Cryo-Cell International, Inc.
Cryo-Cell International, Inc. Fundamental Analysis
Cryo-Cell International, Inc. (CCEL) shows weak financial fundamentals with a PE ratio of 68.36, profit margin of 1.26%, and ROE of -2.74%. The company generates $0.0B in annual revenue with weak year-over-year growth of 2.05%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 27.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CCEL's fundamental strength across five key dimensions:
Efficiency Score
WeakCCEL struggles to generate sufficient returns from assets.
Valuation Score
ModerateCCEL shows balanced valuation metrics.
Growth Score
WeakCCEL faces weak or negative growth trends.
Financial Health Score
ModerateCCEL shows balanced financial health with some risks.
Profitability Score
WeakCCEL struggles to sustain strong margins.
Key Financial Metrics
Is CCEL Expensive or Cheap?
P/E Ratio
CCEL trades at 68.36 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CCEL's PEG of -0.51 indicates potential undervaluation.
Price to Book
The market values Cryo-Cell International, Inc. at -1.84 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.54 times EBITDA. This is generally considered low.
How Well Does CCEL Make Money?
Net Profit Margin
For every $100 in sales, Cryo-Cell International, Inc. keeps $1.26 as profit after all expenses.
Operating Margin
Core operations generate 13.63 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.74 in profit for every $100 of shareholder equity.
ROA
Cryo-Cell International, Inc. generates $0.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cryo-Cell International, Inc. produces operating cash flow of $6.35M, showing steady but balanced cash generation.
Free Cash Flow
Cryo-Cell International, Inc. generates strong free cash flow of $6.05M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.75 in free cash annually.
FCF Yield
CCEL converts 22.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
68.36
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
-1.84
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.86
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.28
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.03
vs 25 benchmark
ROA
Return on assets percentage
0.006
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How CCEL Stacks Against Its Sector Peers
| Metric | CCEL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 68.36 | 29.45 | Worse (Expensive) |
| ROE | -2.74% | 779.00% | Weak |
| Net Margin | 1.26% | -24936.00% (disorted) | Weak |
| Debt/Equity | -0.28 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 0.63 | 4.65 | Weak Liquidity |
| ROA | 0.63% | -19344.00% (disorted) | Weak |
CCEL outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cryo-Cell International, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
4.02%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
-81.84%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-1.64%
Industry Style: Defensive, Growth, Innovation
Declining